Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Patient has medical chart documentation of advanced (unresectable or metastatic) melanoma. * Patient initiated a first-line therapy for the treatment of advanced melanoma during the eligibility period (01 July 2016 to 01 July 2017; index event). * Patient did not receive systemic treatment for their advanced (unresectable or metastatic) melanoma prior to index event * Patient initiated first-line therapy at least six months before the date their chart abstraction initiated Exclusion Criteria: * Patient was enrolled in an investigational drug clinical trial or participating in medical research judged to directly affect how the patient was being monitored/treated while receiving first-line therapy * Patient had another active concurrent malignancy other than advanced melanoma, which required systemic treatment at the time of index event * Part or all of the patient's first-line treatment was received at a different site and the patient's medical chart pertaining to this care is not accessible * Patient medical chart is missing, empty, or not retrievable Other protocol defined inclusion/exclusion criteria could apply